Literature DB >> 2547074

Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands.

B R de Costa1, W D Bowen, S B Hellewell, C George, R B Rothman, A A Reid, J M Walker, A E Jacobson, K C Rice.   

Abstract

The synthesis and in vitro sigma receptor activity of the two diastereomers of U50,488 [(+/-)-2], namely, (1R,2S)-(+)- cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet ami de [(+)-1] and (1S,2R)-(-)-cis-3,4-dichloro- N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide [(-)-1], are described. (+)-1 and (-)-1 were synthesized from (+/-)-trans-N-methyl-2-aminocyclohexanol [(+/-)-3]. Pyridinium chlorochromate (PCC) oxidation of the N-t-Boc-protected derivative of (+/-)-3 afforded (+/-)-2-[N- [(tert-butyloxy)carbonyl]-N-methylamino]cyclohexanone [(+/-)-5]. The sequence of enamine formation with pyrrolidine, catalytic reduction, N-deprotection, and optical resolution afforded (1R,2S)-(-)-cis-2-pyrrolidinyl-N-methylcyclohexylamine [(-)-10] and (1S,2R)-(+)-cis-2-pyrrolidinyl-N-methylcyclohexylamine [(+)-10]. The optical purity (greater than 99.5%) of (-)-10 and (+)-10 was determined by HPLC analysis of the diastereomeric ureas formed by reaction with optically pure (R)-alpha-methylbenzyl isocyanate. The absolute configuration of (-)-10 and (+)-10 was determined by single-crystal X-ray diffractometry of the bis-(R)-mandelate salt. Condensation of optically pure (-)-10 and (+)-10 with 3,4-dichlorophenylacetic acid furnished (+)-1 and (-)-1, respectively. Compounds (+)-1, (-)-1, (-)-2, and (+)-2 were compared for their binding affinities at kappa opioid, sigma, D2-dopamine, and phencyclidine (PCP) receptors in competitive binding assays using [3H]bremazocine ([3H]BREM) or [3H]U69,593, [3H]-(+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [[3H]-(+)-3-PPP], or [3H]-1,3-di(o-tolyl)guanidine ([3H]DTG), [3H]-(-)-sulpiride [[3H]-(-)SULP], and [3H]-1- [1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP), respectively. In the systems examined, (-)-2 exhibited the highest affinity for kappa receptors, with a Ki of 44 +/- 8 nM. However, (-)-2 also showed moderate affinity for sigma receptors, with a Ki of 594 +/- 3 nM [[3H]-(+)-3-PPP]. The (1R,2R)-(+)-enantiomer, (+)-2, had low affinity for both kappa and sigma receptors, exhibiting Ki values of 1298 +/- 49 nM at kappa ([3H]BREM) and 1270 +/- 168 nM at sigma [[3H]-(+)-3-PPP]. In contrast, the chiral cis compounds (+)-1 and (-)-1 showed high affinity for sigma receptors and negligible affinity for kappa opioid receptors in the [3H]BREM assay. Compound (-)-1 exhibited a Ki of 81 +/- 13 nM at sigma receptors [[3H]-(+)-3-PPP] and 250 +/- 8 nM ([3H]DTG).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547074     DOI: 10.1021/jm00128a050

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

2.  Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.

Authors:  Jing Zhang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2009-02-11       Impact factor: 1.810

3.  Modulation of the induction of ornithine decarboxylase by some opioid receptor agonists in immune cells and cardiomyocytes.

Authors:  C Pignatti; I Stanic; C Stefanelli; B Tantini; C Rossoni; F Flamigni
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.396

Review 4.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

5.  Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488.

Authors:  Victoria C Smith; Laura A T Cleghorn; Andrew Woodland; Daniel Spinks; Irene Hallyburton; Iain T Collie; N Yi Mok; Suzanne Norval; Ruth Brenk; Alan H Fairlamb; Julie A Frearson; Kevin D Read; Ian H Gilbert; Paul G Wyatt
Journal:  ChemMedChem       Date:  2011-08-10       Impact factor: 3.466

6.  Asymmetric Amination of meso-Epoxide with Vegetable Powder as a Low-Toxicity Catalyst.

Authors:  Yuki Takeuchi; Tatsuhiro Asano; Kazuya Tsuzaki; Koichi Wada; Hiroyuki Kurata
Journal:  Molecules       Date:  2020-07-13       Impact factor: 4.411

7.  Enantiomerically Pure Quinoline-Based κ-Opioid Receptor Agonists: Chemoenzymatic Synthesis and Pharmacological Evaluation.

Authors:  Benedikt Martin; Dirk Schepmann; Freddy A Bernal; Thomas J Schmidt; Tao Che; Karin Loser; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2020-07-02       Impact factor: 3.466

8.  Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.

Authors:  Giovanni Tangherlini; Frederik Börgel; Dirk Schepmann; Samuel Slocum; Tao Che; Stefan Wagner; Katrin Schwegmann; Sven Hermann; Nadine Mykicki; Karin Loser; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2020-09-01       Impact factor: 3.466

9.  Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective.

Authors:  Antonino N Fallica; Valeria Pittalà; Maria N Modica; Loredana Salerno; Giuseppe Romeo; Agostino Marrazzo; Mohamed A Helal; Sebastiano Intagliata
Journal:  J Med Chem       Date:  2021-06-02       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.